Ocugen OCGN 深 沪
等待开盘 10-07 09:30:00 美东时间
1.04
0.000
0.00%
华盛通- 最 高1.43
- 今 开1.06
- 成交量 524.89万股
- 最 低 0.97
- 昨 收 1.04
- 总市值 22.46万
- 52周最高 2.725
- 市盈率 静 --
- 换手率 2430.07%
- 52周最低 0.97
- 委 比 43.43%
- 总股本 0.00亿
- 历史最高 18.77
- 量 比 1.17
- 振 幅 44.23%
- 历史最低 0.17
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SCYNEXIS Appoints Sanjay Subramanian As CFO, Effective September 9
Mr. Subramanian brings more than 20 years of finance, capital markets, business development and operational leadership experience across the biotechnology, pharmaceutical and healthcare sectors. Most recently, he served
09-10 20:01
Ocugen Completes Enrollment In Late-Stage Blindness Trial, Eyes FDA Filing In 2026
Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that enrollment is now complete for the OCU400 Phase 3 liMeliGhT clinical
03-02 20:10
Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage
Ocugen reports early phase 2 data showing its eye gene therapy reduced lesion growth by up to 54%, with no serious safety issues.
01-16 02:15
OS Therapies Bone Cancer Trial Data Strengthens FDA Case
OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eligibility for a valuable priority review voucher.
01-16 01:30
苹果、微软、亚马逊、Meta财报来袭
作者丨Oliver Rodzianko 编译 | 华尔街大事件 本周科技巨头、能源巨头、金融公司、医疗保健行业领袖和消费者品牌将陆续发布大量财报。 焦点将集中...
2025-07-28 20:40
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
Ocugen's OCU410ST gene therapy for Stargardt disease has received FDA clearance for a Phase 2/3 trial, following successful Phase 1 results showing safety, slowed lesion growth, and improved visual function. The trial aims to evaluate its effectiveness in reducing atrophic lesions and improving vision.
2025-06-16 11:02
Ocugen To Present at BIO International Convention 2025
Ocugen Inc. will present at the 2025 BIO International Convention, showcasing its novel gene therapy platform targeting blindness diseases. The company recently signed a deal in Korea and is on track for a 2026 BLA filing. CEO Dr. Shankar Musunuri will speak at the event, highlighting Ocugen's progress and collaborations to advance its gene therapies.
2025-06-11 11:30
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Ocugen Inc. has signed a binding term sheet with a leading Korean pharmaceutical company for exclusive rights to its gene therapy, OCU400, targeting retinitis pigmentosa (RP). The agreement includes up to $11 million in upfront fees and milestones, 25% royalties on sales, and Ocugen manufacturing the therapy. With an estimated 15,000 RP patients in South Korea, the partnership aims to expand Ocugen's reach and benefit patients.
2025-06-05 11:02
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
Ocugen's OCU410ST has received Rare Pediatric Disease Designation for treating <em>ABCA4</em>-associated retinopathies, including Stargardt disease. This designation highlights the urgency for a treatment option for children with this rare and life-threatening disease, affecting about 100,000 people globally. Ocugen may qualify for a Priority Review Voucher, potentially worth $100 million, and plans to launch a Phase 2/3 trial soon.
2025-05-27 11:02
